



26 August 2025



PolyNovo Limited ABN 96 083 866 862

2/320 Lorimer Street Port Melbourne VIC Australia 3207

P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099

ASX Announcement

Webcast Recording for the FY25 Results Presentation

For shareholders and other interested parties who were unable to attend the FY25 results presentation live, or would like the opportunity to view it again, the recording can be viewed at the link below.

https://vimeo.com/1113055091/5142d6887f

- CEO update (timestamp 1:40)
- Financial results (timestamp 9:23)
- Chairman's commentary (timestamp 16:20)
- Q&A (timestamp 28:00)

This announcement has been authorised by PolyNovo Company Secretary, Jan Gielen.

About PolyNovo®

PolyNovo is a disruptive medical technology company, based in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 70,000+ patients across 46 countries, the company is investing for growth with new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.